GRCE
Grace Therapeutics, Inc.
Key Financials
Net Income
$-9568000
↑ 25.6%
Operating Income
$-16679000
↓ 29.8%
Revenue
$100.0M
N/A
EPS (Diluted)
$-0.79
↑ 41.5%
Total Liabilities
$5.4M
↓ 53.4%
Total Assets
$72.0M
↓ 1.8%
Shareholders' Equity
$66.6M
↑ 7.9%
Cash & Equivalents
$22.1M
↓ 3.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/5/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 4/27/2026 | View on SEC |
| 8-K | 4/27/2026 | View on SEC |
| 8-K | 4/23/2026 | View on SEC |
| SCHEDULE 13G/A | 2/17/2026 | View on SEC |
| SCHEDULE 13G/A | 2/13/2026 | View on SEC |
| 8-K | 2/12/2026 | View on SEC |
| 10-Q | 2/12/2026 | View on SEC |
| SCHEDULE 13G/A | 1/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GRCE |
| Company Name | Grace Therapeutics, Inc. |
| CIK | 1444192 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 0331 |
| State of Incorporation | DE |
| Phone | 609-322-1602 |